Combined DaT imaging and olfactory testing for differentiating parkinsonian disorders

International Journal of Clinical Practice

Volumn 68, Issue 11, 2014, Pages 1345-1351

  Borghammer, P ^a   Knudsen, K ^a   Ostergaard K ^a   Danielsen, E H ^a   Pavese, N ^a,b   Arveschoug, A ^a   Bluhme, H ^a   Bode, M ^c   Morsing, A ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE TRANSPORTER;

ADULT; ALZHEIMER DISEASE; ANOSMIA; ARTICLE; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; DIFFUSE LEWY BODY DISEASE; DISEASE CLASSIFICATION; DOPAMINERGIC SYSTEM; FEMALE; FOLLOW UP; HUMAN; HUNTINGTON CHOREA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR IMAGING; PARKINSONISM; PROGRESSIVE SUPRANUCLEAR PALSY; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMELLING; SPECT SCANNER; SPINOCEREBELLAR DEGENERATION; AGED; DIFFERENTIAL DIAGNOSIS; ECHOGRAPHY; PARKINSON DISEASE; PREDICTIVE VALUE; SCINTISCANNING; UTILIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; DIAGNOSIS, DIFFERENTIAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEWY BODY DISEASE; MALE; MIDDLE AGED; PARKINSON DISEASE; PARKINSONIAN DISORDERS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84916603327     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12445     Document Type: Article

References (29)

1. Bajaj N, Hauser RA, Grachev ID,. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2013; 84: 1288-95.
2. Seifert KD, Wiener JI,. The impact of DaTscan on the diagnosis and management of movement disorders: a retrospective study. Am J Neurodegener Dis 2013; 2: 29-34.
3. Kim YJ, Ichise M, Ballinger JR, et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 2002; 17: 303-12.
4. Sudmeyer M, Antke C, Zizek T, et al. Diagnostic accuracy of combined FP-CIT, IBZM, and MIBG scintigraphy in the differential diagnosis of degenerative parkinsonism: a multidimensional statistical approach. J Nucl Med 2011; 52: 733-40.
5. Jakobson Mo S, Linder J, Forsgren L, et al. Pre- and postsynaptic dopamine SPECT in idiopathic Parkinsonian diseases: a follow-up study. BioMed Res Int 2013; 2013: 143532.
6. Doty RL,. The olfactory system and its disorders. Semin Neurol 2009; 29: 74-81.
7. Sharma JC, Turton J,. Olfaction, dyskinesia and profile of weight change in Parkinson's disease: identifying neurodegenerative phenotypes. Parkinsonism Relat Disord 2012; 18: 964-70.
8. Katzenschlager R, Lees AJ,. Olfaction and Parkinson's syndromes: its role in differential diagnosis. Curr Opin Neurol 2004; 17: 417-23.
9. Wenning GK, Shephard B, Hawkes C, et al. Olfactory function in atypical parkinsonian syndromes. Acta Neurol Scand 1995; 91: 247-50.
10. Hoyles K, Sharma JC,. Olfactory loss as a supporting feature in the diagnosis of Parkinson's disease: a pragmatic approach. J Neurol 2013; 260: 2951-8.
11. Koch W, Radau PE, Hamann C, Tatsch K,. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. J Nucl Med 2005; 46: 1109-18.
12. Doty RL, Marcus A, Lee WW,. Development of the 12-item Cross-Cultural Smell Identification Test (CC-SIT). Laryngoscope 1996; 106: 353-6.
13. Doty RL, Shaman P, Dann M,. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav 1984; 32: 489-502.
14. Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003; 18: 467-86.
15. Marshall VL, Patterson J, Hadley DM, et al. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl Med Commun 2006; 27: 933-7.
16. Haehner A, Hummel T, Reichmann H,. Olfactory loss in Parkinson's disease. Parkinsons Dis 2011; 2011: 450939.
17. Silveira-Moriyama L, Mathias C, Mason L, et al. Hyposmia in pure autonomic failure. Neurology 2009; 72: 1677-81.
18. Muller A, Mungersdorf M, Reichmann H, et al. Olfactory function in Parkinsonian syndromes. J Clin Neurosci 2002; 9: 521-4.
19. Silveira-Moriyama L, Hughes G, Church A, et al. Hyposmia in progressive supranuclear palsy. Mov Disord 2010; 25: 570-7.
20. Doty RL, Deems DA, Stellar S,. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988; 38: 1237-44.
21. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 2008; 63: 167-73.
22. Hughes AJ, Daniel SE, Kilford L, Lees AJ,. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4.
23. Rajput AH, Rozdilsky B, Rajput A,. Accuracy of clinical diagnosis in parkinsonism-a prospective study. Can J Neurol Sci 1991; 18: 275-8.
24. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ,. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861-70.
25. Hughes AJ, Daniel SE, Lees AJ,. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001; 57: 1497-9.
26. Hummel T, Kobal G, Gudziol H, Mackay-Sim A,. Normative data for the "Sniffin' Sticks" including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects. Eur Arch Otorhinolaryngol 2007; 264: 237-43.
27. Casjens S, Eckert A, Woitalla D, et al. Diagnostic value of the impairment of olfaction in Parkinson's disease. PLoS ONE 2013; 8: e64735.
28. Gamez J, Lorenzo-Bosquet C, Cuberas-Borros G, et al. Does reduced [(123)I]-FP-CIT binding in Huntington's disease suggest pre-synaptic dopaminergic involvement? Clin Neurol Neurosurg 2010; 112: 870-5.
29. Salvatore E, Varrone A, Sansone V, et al. Characterization of nigrostriatal dysfunction in spinocerebellar ataxia 17. Mov Disord 2006; 21: 872-5.